AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74.[2] The company's primary product is Humira (adalimumab) ($14billion in 2023 revenues, 27percent of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
It developed Skyrizi ($7.8billion in 2023 revenues), an interleukin-23 (IL-23) inhibitor also used to treat autoimmune diseases. Its other major products include Botox ($5.7billion in 2023 revenues), Imbruvica to treat cancer ($3.6billion in 2023 revenues), Rinvoq to treat arthritis ($4billion in 2023 revenues), Venclexta to treat leukemia and lymphoma ($2.3billion in 2023 revenues), Vraylar to treat schizophrenia and bipolar disorder ($2.7billion in 2023 revenues), and Mavyret to treat Hepatitis C ($1.4billion in 2023 revenues).[1] The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.[1][3]
In 2023, Humira began facing competition from a biosimilar developed by Amgen. The company is also developing a drug for Parkinson's disease that could be a blockbuster drug in 2027 and is awaiting approval from the Food and Drug Administration for epcoritamab, a blood-cancer therapy under development in partnership with Genmab.[4]
The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'.[5]
^ abc"AbbVie Inc. 2023 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. 20 February 2024.
^"The Global 2000 2023". Forbes. Archived from the original on 2024-01-29. Retrieved 2024-02-07.
^Carroll, John (October 25, 2019). "AbbVie doubles down on cystic fibrosis R&D, adding a new drug to the pipeline as Vertex seals its domination of the field with Trikafta OK". EndpointNews.
^Hopkins, Jared S. (February 6, 2023). "AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira". The Wall Street Journal.
^"Abbott Selects AbbVie as New Name for Future Research-Based Pharmaceutical Company". Abbott MediaRoom (Press release). March 21, 2012.
2015. Retrieved June 5, 2015. "Abbvie Terminates Development Deal with Halozyme – GEN". GEN. 21 November 2016. "AbbVie to Acquire Stemcentrx for Up to...
Rosenblum Sues Pharmaceutical Giants AbbVie and Besins". Oregon Department of Justice. Retrieved 2023-01-21. "AbbVie Inc., et al". Federal Trade Commission...
products. It split off its research-based pharmaceuticals business into AbbVie in 2013. Abbott's products include Pedialyte, Similac, BinaxNOW, Ensure...
and $825 million in milestones. Pharmacyclics was acquired by AbbVie in May 2015, and Abbvie projected global sales of US$1 billion in 2016 and $5 billion...
Pharmaceuticals for $40.5 billion. In June 2019, U.S. pharmaceutical company AbbVie announced it had reached an agreement to acquire Allergan for $63 billion...
AbbVie (Press release). 28 September 2021. Archived from the original on 28 September 2021. Retrieved 29 September 2021 – via PR Newswire. "AbbVie Announces...
(PDUFA) date. AbbVie Inc. manufactures Venclexta. It is marketed by both Abbvie and Genentech USA, which is a member of the Roche Group. AbbVie and Genentech...
Doxycycline is a broad-spectrum antibiotic of the tetracycline class used in the treatment of infections caused by bacteria and certain parasites. It is...
depressive disorder. It is being developed jointly by AbbVie and Gedeon Richter Plc, with AbbVie responsible for commercialization in the US, Canada, Japan...
companies, one retaining the Abbott name and the other named AbbVie. As a result, AbbVie took over development and marketing of Humira. The brand name...
September 2021. "Rinvoq (Abbvie Pty Ltd)". Archived from the original on 9 November 2022. Retrieved 9 November 2022. "Rinvoq (Abbvie Pty Ltd)". Therapeutic...
Fluoxetine, sold under the brand name Prozac, among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used...
bispecific CD20-directed CD3 T-cell engager. Epcoritamab was co-developed by AbbVie and Genmab. Epcoritamab was approved for medical use in the United States...
Cefdinir, sold under the brand name Omnicef among others, is an antibiotic used to treat pneumonia, otitis media, strep throat, and cellulitis. It is a...
"Three factors that drove the transformational integration of AbbVie, Allergan". abbvie.com. November 30, 2022. Retrieved December 14, 2023. Avalos, George...
commercial product. In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire Pharmacyclics, as well as its lead anti-cancer...
some cases, the antibody also has anticancer activity. In November 2023, AbbVie, an American pharmaceutical company, announced it was buying ImmunoGen for...
Targets". Endometriosis News. Retrieved 14 October 2016. "AbbVie : FDA moves the goal line on AbbVie's endometriosis drug elagolix". 4-traders. April 11, 2018...
Ketorolac, sold under the brand name Toradol among others, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain. Specifically it is recommended...
Ursodeoxycholic acid (UDCA), also known as ursodiol, is a secondary bile acid, produced in humans and most other species from metabolism by intestinal...
Levothyroxine, also known as L-thyroxine, is a synthetic form of the thyroid hormone thyroxine (T4). It is used to treat thyroid hormone deficiency (hypothyroidism)...
Botulinum toxin, or botulinum neurotoxin (commonly called botox), is a highly potent neurotoxic protein produced by the bacterium Clostridium botulinum...
Global Information
US$54.32 billion (2023)